Armistice Capital reports 8.08M Citius Oncology shares

Citius Oncology reported that Armistice Capital, LLC and Steven Boyd beneficially own 8,078,404 shares, representing 9.79% of the common stock.

Rhea-AI Filing Summary

Citius Oncology reported that Armistice Capital, LLC and Steven Boyd beneficially own 8,078,404 shares, representing 9.79% of the common stock. The position is held through Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager; the Master Fund disclaims beneficial ownership arising from its lack of voting or dispositive power under the Investment Management Agreement.

The filing is a joint Schedule 13G/A signed by Steven Boyd on February 17, 2026 reporting shared voting and dispositive power over the 8,078,404 shares.

Insights

Institutional Ownership Analyst

Armistice Capital reports a near-10% stake in Citius Oncology via its Master Fund.

The filing states Armistice Capital, as investment manager, and Steven Boyd, as managing member, report beneficial ownership of 8,078,404 shares, or 9.79%, with shared voting and dispositive power.

This ownership level is large enough to be visible to investors but the filing frames it as management of a fund rather than direct ownership; subsequent disclosures may clarify any changes in voting or disposition intentions.

Corporate Governance Specialist

Reporting attributes control to the investment manager while the Master Fund disclaims direct beneficial ownership.

The statement explains that the Master Fund is the direct holder and Armistice Capital exercises voting and investment power under an Investment Management Agreement; the Master Fund "disclaims beneficial ownership" of the securities it holds because it lacks voting/dispositive authority.

For governance impact, note the filing records shared voting and dispositive power; any board engagement or activist intentions would require further filings or disclosures.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Armistice Capital report in Citius Oncology (CTOR)?

Armistice Capital reports beneficial ownership of 8,078,404 shares, equal to 9.79% of the common stock. The position is held through the Armistice Capital Master Fund Ltd., with Armistice Capital exercising voting and investment power under an Investment Management Agreement.

Who is reported as the filing parties in the Schedule 13G/A for CTOR?

The filing names Armistice Capital, LLC and Steven Boyd as joint reporting persons. Steven Boyd is listed as Managing Member and signed the amendment on February 17, 2026 on behalf of both reporting persons.

Does the Master Fund claim beneficial ownership of the CTOR shares?

No; the Master Fund specifically disclaims beneficial ownership of the reported securities because it says it lacks voting and dispositive power. Armistice Capital, as investment manager, reports the shared voting and dispositive authority instead.

What voting and disposition powers are reported for the CTOR shares?

The Schedule 13G/A reports 0 shares with sole voting or dispositive power and 8,078,404 shares with shared voting and dispositive power. These figures are included in Item 4 of the filing as the basis for the 9.79% ownership percentage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 09:52 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

CITIUS ONCOLOGY, INC.

(Name of Issuer)

Common stock, $0.0001 par value

(Title of Class of Securities)

17331Y109

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 17331Y109

1

Names of Reporting Persons

Armistice Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,078,404.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,078,404.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,078,404.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 17331Y109

1

Names of Reporting Persons

Steven Boyd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,078,404.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,078,404.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,078,404.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CITIUS ONCOLOGY, INC.
(b)	Address of issuer's principal executive offices: 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD, NJ, 07016
Item 2.
(a)	Name of person filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
(b)	Address or principal business office or, if none, residence: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
(c)	Citizenship: Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)	Title of class of securities: Common stock, $0.0001 par value
(e)	CUSIP No.: 17331Y109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 8,078,404.00
(b)	Percent of class: 9.79%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 8,078,404.00
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 8,078,404.00 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Armistice Capital, LLC

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd - Managing Member
Date:	02/17/2026

Steven Boyd

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd
Date:	02/07/2026

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd